NASDAQ
02.09.25 | 22:00
9,280 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.06. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| IMMUNOME Aktie jetzt für 0€ handeln | |||||
| 19.05. | Immunome stock rating cut to Hold by Boral Capital | 2 | Investing.com | ||
| 12.05. | Immunome GAAP EPS of -$0.52 beats by $0.14, revenue of $2.93M beats by $2.47M | 1 | Seeking Alpha | ||
| 12.05. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | 3 | Insider Monkey | ||
| 26.03. | Immunome stock rises after insider purchase | 1 | Seeking Alpha | ||
| 20.03. | Immunome stock target cut to $25 by Guggenheim | 1 | Investing.com | ||
| 19.03. | Immunome Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Immunome GAAP EPS of -$5.00 misses by $0.62, revenue of $9.04M misses by $0.37M | 1 | Seeking Alpha | ||
| 19.03. | Immunome Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 19.03. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.11.24 | Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update | 202 | Business Wire | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced... ► Artikel lesen | |
| 29.10.24 | Immunome, Inc.: Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 | 271 | Business Wire | IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected in 1Q25 HC74, Immunome's... ► Artikel lesen | |
| 13.09.24 | Immunome, Inc.: Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 | 341 | Business Wire | Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 20,845 | +0,24 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,000 | +1,77 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| TEMPUS AI | 68,00 | +0,74 % | Forecasting The Future: 5 Analyst Projections For Tempus AI | ||
| RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| OCULAR THERAPEUTIX | 10,730 | -1,60 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| MACROGENICS | 1,600 | +7,31 % | MacroGenics, Inc.: MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities | Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement... ► Artikel lesen | |
| CORCEPT THERAPEUTICS | 60,04 | -2,06 % | Can Korlym Drive Corcept's Growth Through the Rest of 2025? | ||
| ULTRAGENYX | 28,600 | +3,62 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for... ► Artikel lesen | |
| AMNEAL PHARMACEUTICALS | 8,250 | 0,00 % | Amneal Pharmaceuticals, Inc.: Amneal Reports Second Quarter 2025 Financial Results | ? Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ?? Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ?? Raising 2025 Full Year... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,090 | 0,00 % | Enveric Biosciences Relocates HQ to Cambridge, MA | ||
| ABSCI | 2,340 | 0,00 % | Absci Corporation: Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg | VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 6,140 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness | ||
| RAKOVINA THERAPEUTICS | 0,266 | -3,62 % | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update | VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
IMMUNOME INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,280 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOME INC finden Sie auf Wallstreet Online.